In a surprising result for an ongoing medical trial, 12 rectal cancer patients were completely healed of the disease after taking a drug for six months. The patients underwent a series of medical exams — physical exam, endoscopy, bioscopy, PET scans, and MRI scans — and none of the reports showed any signs of the tumour.
The findings were published in a paper in the New England Journal of Medicine. The paper lists the names of 32 authors.
The initial purpose of this study was listed to find out whether the study drug, TSR-042 (commonly called dostarlimab), followed by standard chemoradiotherapy and standard surgery is an effective treatment for advanced deficient MisMatch Repair (dMMR) solid tumours.
